clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with aids.

NLM AIDSLINE Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Newman SL; Flanigan TP; Fisher A; Rinaldi MG; Stein M; Vigilante K;
April 30, 1995

Clin Infect Dis. 1994 Oct;19(4):684-6. Unique Identifier : AIDSLINE Eight cases of severe mucosal candidiasis in patients with AIDS who were taking fluconazole at a dosage of 400-800 mg/d are described. Candida albicans alone or in conjunction with Torulopsis glabrata or Candida stellatoidea was isolated from each patient. In vitro susceptibility testing demonstrated resistance to fluconazole in all eight cases. All tested isolates were susceptible to amphotericin B, and six of eight isolates tested were susceptible to itraconazole. All individuals were severely immunocompromised (CD4 lymphocyte counts: mean, 15/mm3; range, 6-39/mm3) and had been receiving prophylaxis with fluconazole for a mean of only 3 months (range, 1-7 months). The occurrence of candidal mucositis in patients receiving high doses of fluconazole is a matter of concern that requires further study in regard to the causes, prevention, and treatment of the disease. Adult AIDS-Related Opportunistic Infections/DRUG THERAPY/IMMUNOLOGY Candida/DRUG EFFECTS Candidiasis, Oral/DRUG THERAPY/IMMUNOLOGY Candidiasis, Vulvovaginal/DRUG THERAPY/IMMUNOLOGY CD4 Lymphocyte Count Drug Resistance, Microbial Female Fluconazole/*PHARMACOLOGY Human Immunocompromised Host Male JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 UN: AIDS Deaths Down, Treatment Up in Africa Nairobi Solidarity Rally May 10 Proclaims: “No Retreat on AIDS – Treatment for All”AHF: Global AIDS Patients, Doctors Lobby Congress on PEPFAR Reauth International AIDS Advocates Demand China Give $1 Billion to Global Fund Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness UNITED STATES: How Sexual Stigma Is Undermining HIV Treatment on American Indian Reservations Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog
Information in this article was accurate in April 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.